Finecef-o Case Study 6: June

15 Questions | Total Attempts: 161

SettingsSettingsSettings
Finecef-o Case Study 6: June - Quiz

Dear Colleagues, This is the first E-Sat for the month of June, which is on Finecef-O case study 6 & also on the Finecef LBL. This quiz is open from 4th June 10 a. M till 12 th June 11. 55 pm. Requesting, to attempt only once, as only your first attempt will be considered your score. Wish you all the very best !


Questions and Answers
  • 1. 
    Cefpodoxime is a first choice in RTI because
    • A. 

      Efficacy is equivalent to Ceftriaxone

    • B. 

      Achieves high tissue concentrations

    • C. 

      Wide spectrum of coverage

    • D. 

      All the statements are true.

  • 2. 
    Maximum inhibition of endotoxins 
    • A. 

      Reduce Fever

    • B. 

      Reduce congestion

    • C. 

      Reduce cough

    • D. 

      All the statements are true.

  • 3. 
    The inhibition of endotoxins is done by
    • A. 

      Ofloxacin

    • B. 

      Cefpodoxime

    • C. 

      Ofloxacin+Cefpodoxime

    • D. 

      None

  • 4. 
    In the case study mentioned the 56 year old man did not have a history of 
    • A. 

      Diabetes

    • B. 

      COPD

    • C. 

      Dyspnea

    • D. 

      Hypertension

  • 5. 
    The diagnosis in the patient mentioned in the case study was
    • A. 

      COPD

    • B. 

      Pneumonia

    • C. 

      Asthma

    • D. 

      Typhoid

  • 6. 
    The treatment given to the patient was
    • A. 

      Finecef O BID for 7 days+ 1 tablet paracetamol

    • B. 

      Metformin 500 mg after lunch+Glimepride 1mg Before breakfast

    • C. 

      Salbutamol 2mg TDS

    • D. 

      All the medications

  • 7. 
    Ofloxacin role in this case 
    • A. 

      Excellent activity against gram positive

    • B. 

      Excellent activity against Atypical bacteria

    • C. 

      Excellent activity against Gram negative bacteria

    • D. 

      Excellent activity against Gm positive, Gm negative and atypical bacteria.

  • 8. 
    Cefpodoxime has a good Tissue pentration and Inhibition of endotoxins
    • A. 

      FALSE

    • B. 

      TRUE

  • 9. 
    Cefpodoxime does not cover which of the following bacteria
    • A. 

      Streptococcus pneumonia

    • B. 

      Klebsiella pneumonia

    • C. 

      Hemophilus influenza

    • D. 

      Mycoplasma pneumonia

  • 10. 
    As per the case study The outcome of the treatment was 
    • A. 

      Cough was reduced

    • B. 

      Fever reduction in 48 hours after starting the treatment

    • C. 

      Dyspnea was significantly lesser

    • D. 

      All the statements are true.

  • 11. 
    Dispersibility is defined as, distributes as fine particles throughout a medium
    • A. 

      TRUE

    • B. 

      FALSE

  • 12. 
    Dispersibility for Cefpodoxime is all so very important because,
    • A. 

      Cefpodoxime has a very high bio-availability

    • B. 

      Solubility of Cefpodoxime is very poor

    • C. 

      Cefpodoxime has very low bio-availability

    • D. 

      Cefpodoxime is insoluble

  • 13. 
    Solubility is directly proportional to dispersibility
    • A. 

      FALSE

    • B. 

      TRUE

  • 14. 
    Increased solubility increases the
    • A. 

      Bio-availability

    • B. 

      Peak Plasma Concentration

    • C. 

      Half life of Cefpodoxime

    • D. 

      First pass metabolism of Cefpodoxime

  • 15. 
    Finecef gives advantage of
    • A. 

      A suspension

    • B. 

      A dispersible tablet

    • C. 

      Both tablet & suspension

    • D. 

      A Readymix

Related Topics
Back to Top Back to top